Advertisement
Organisation › Details
CNES (FR)
CNES is the government agency responsible for shaping France’s space policy and executing it in Europe. Its task is to conceive and orbit satellites, invent the space systems of the future and nurture new services to aid us in our daily lives. Founded in 1961, it is the initiator of major space projects, launch vehicles and satellites, and the partner of choice for industry, supporting exports and fuelling innovation. CNES is working to further applications in five core areas of focus: Ariane, science, Earth observation, telecommunications and defence. CNES is a key player driving technology research, economic development and industrial policy for the nation. It also fosters scientific collaborations and has forged numerous international partnerships. France, represented by CNES, is the leading contributor to the European Space Agency (ESA), which conducts Europe’s space policy on behalf of its 22 member states. *
Start | 1961-01-01 established | |
Group | France (govt) | |
Region | France_oo | |
Country | France | |
City | n. a. Paris | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: bioMérieux S.A.. (1/15/18). "Press Release: CNES and bioMérieux Extend Their Collaboration on Aquapad, a Unique Water Quality Testing Tool". | ||
Record changed: 2024-02-12 |
Advertisement
More documents for France (govt)
- [1] SurgeCare SAS. (3/27/24). "Press Release: Surge Announces Closing of a €7.5 Million Fundraising Round to Decrypt the Immune System and Transform Precision Medicine". Paris....
- [2] Global Bioenergies S.A.. (10/4/23). "Press Release: French Government Awards Global Bioenergies €16.4 Million to Help Fund Construction of the World’s First Biosourced Isobutene Plant". Évry....
- [3] EverImmune. (9/19/23). "Press Release: EverImmune Secures €3.5 Million in Financing from Bpifrance". Villejuif....
- [4] Biper Therapeutics SAS. (2/14/23). "Press Release: Biper Therapeutics Raises €1.25 Million in Seed Funding to Develop First-in-Class Small Molecules to Treat Gastrointestinal Cancers". Strasbourg....
- [5] Theranexus S.A.. (10/20/22). "Press Release: Theranexus and Inserm Transfert Sign a Strategic Alliance to Identify Advanced Therapy Drug Candidates for Rare Neurological Diseases". Lyon....
- [6] AdBio Partners SAS. (5/3/22). "Press Release: AdBio Partners Welcomes Inserm Transfert as Investor in Second Fund – AFB Fund II". Paris....
- [7] Hemerion Therapeutics SAS. (4/14/22). "Press Release: Hemerion Therapeutics successfully raises over €3.5 million: a new hope for the treatment of brain cancer". Villeneuve d’Ascq....
- [8] SeaBeLife SAS. (3/14/22). "Press Release: SeaBeLife Receives Close to €1.4M Deep Tech Financing from Bpifrance". Roscoff....
- [9] Cell-Easy. (2/28/22). "Press Release: The OPTI-STEM Consortium Led by CDMO Cell-Easy Receives €7M from the French Government and Bpifrance and €800,000 from the Occitanie Region to Democratize Access to Cell Therapy in France and Europe". Toulouse, La...
- [10] Amolyt Pharma SAS. (2/4/22). "Press Release: Amolyt Pharma Selected for the French Tech 120 Program". Lyon & Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top